Champions Oncology (CSBR) Cash from Operations (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Cash from Operations of 1339000.0 in Q1 2026, up 22.82% quarter-over-quarter from 1735000.0 in Q4 2025, and down 373.27% on a YoY basis from 490000.0 in Q1 2025.
Champions Oncology (CSBR) Cash from Operations (2010 - 2026) Analysis & Trends
Champions Oncology's Cash from Operations history runs 17 years deep, the most recent figure standing at 1339000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 373.27% year-over-year to 1339000.0; the TTM figure through Jan 2026 stood at 4394000.0 (up 438.52% YoY), while the FY2025 annual figure was 7386000.0, up 220.35% from the prior year.
- Cash from Operations was 1339000.0 for Q1 2026 at Champions Oncology, up from 1735000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 6868000.0 in Q2 2025 to a low of 3991000.0 in Q3 2023.
- Historically, Cash from Operations has averaged 458823.53 across 5 years, with a median of 311000.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations soared 3053.33% in 2022, then plunged 1946.67% in 2023.
- A 5-year view of Cash from Operations shows it stood at 3286000.0 in 2022, then plunged by 82.08% to 589000.0 in 2023, then tumbled by 148.05% to 283000.0 in 2024, then sank by 513.07% to 1735000.0 in 2025, then increased by 22.82% to 1339000.0 in 2026.
- The last three Cash from Operations figures came in at 1339000.0 (Q1 2026), 1735000.0 (Q4 2025), and 600000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -1.34 Mn |
| Jan 31, 2026 | -1.34 Mn |
| Oct 31, 2025 | -1.74 Mn |
| Oct 31, 2025 | -1.74 Mn |
| Jul 31, 2025 | 600,000.00 |
| Jul 31, 2025 | 600,000.00 |
| Apr 30, 2025 | 6.87 Mn |
| Apr 30, 2025 | 6.87 Mn |
| Jan 31, 2025 | 490,000.00 |
| Jan 31, 2025 | 490,000.00 |
| Oct 31, 2024 | -283,000.00 |
| Oct 31, 2024 | -283,000.00 |
| Jul 31, 2024 | 311,000.00 |
| Jul 31, 2024 | 311,000.00 |
| Apr 30, 2024 | -1.82 Mn |
| Apr 30, 2024 | -1.82 Mn |
| Jan 31, 2024 | -919,000.00 |
| Jan 31, 2024 | -919,000.00 |
| Oct 31, 2023 | 589,000.00 |
| Oct 31, 2023 | 589,000.00 |